Chinook to spin AbbVie castoff into personalized kidney disease candidate

The trend towards personalized medicine for renal diseases continues with Chinook’s licensing of atrasentan from AbbVie. The biotech plans to put its precision medicine spin on the endothelin A receptor while transitioning it from the large diabetic nephropathy indication to a rare disease setting.

Chinook Therapeutics Inc. licensed worldwide, exclusive rights to atrasentan for all indications for an undisclosed upfront payment plus milestones and royalties. AbbVie Inc. (NYSE:ABBV) also took an equity stake in the company. ...